Skip to main content
SpringerLink
Log in

Advances in the Diagnosis and Classification of Chronic Lymphoproliferative Disorders

  • Chapter
Hematopathology in Oncology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 121))

Summary

In this review, we have highlighted recent advances in chronic lymphoproliferative disorders that commonly involve the peripheral blood. As we have seen, our concepts of certain diseases are changing. Molecular genetic and immunophenotypic studies are allowing more precise characterization of CLL and defining important biologic markers that predict clinical behavior. Prolymphocytic leukemia is now more narrowly defined and its relationship to nucleolated variants of MCL is now apparent. With new reagents and techniques applied to problems such as identification of Sezary cells and T-cell monoclonality determination, our ability to diagnose, monitor, and provide prognostic information is improving. Insight into the biology of these diseases also may provide new therapeutic targets in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Oscier DG, Matutes E, Copplestone A et al. Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12. Br J Haematol. 1997;98:934–939

    Article  CAS  PubMed  Google Scholar 

  2. Matutes E, Oscier D, Garcia-Marco J et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol. 1996;92:382–388

    Article  CAS  PubMed  Google Scholar 

  3. Frater JL, McCarron KF, Hammel JP et al. Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically. Am J Clin Pathol. 2001;116:655–664

    Article  CAS  PubMed  Google Scholar 

  4. Criel A, Verhoef G, Vlietinck R et al. Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases. Br J Haematol. 1997;97:383–391

    Article  CAS  PubMed  Google Scholar 

  5. Vallespi T, Montserrat E, Sanz MA. Chronic lymphocytic leukaemia: prognostic value of lymphocyte morphological subtypes. A multivariate survival analysis in 146 patients. Br J Haematol. 1991;77:478–485

    CAS  PubMed  Google Scholar 

  6. Cheson BD, Bennett JM, Rai KR et al. Guidlines for clincial protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-Sponsored Working Group. Am J Hematol. 1988;29:152–163

    Article  CAS  PubMed  Google Scholar 

  7. Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997

    CAS  PubMed  Google Scholar 

  8. Rai KR, Sawitsky A, Cronkite EP et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234

    CAS  PubMed  Google Scholar 

  9. Dohner H, Stilgenbauer S, Dohner K et al. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med. 1999;77:266–281

    Article  CAS  PubMed  Google Scholar 

  10. Finn WG, Thangavelu M, Yelavarthi KK et al. Karyotype correlates with peripheral blood morphology and immunophenotype in chronic lymphocytic leukemia. Am J Clin Pathol. 1996;105:458–467

    CAS  PubMed  Google Scholar 

  11. Dohner H, Stilgenbauer S, Benner A et al. Genomic alterations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916

    Article  CAS  PubMed  Google Scholar 

  12. Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression As novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847

    CAS  PubMed  Google Scholar 

  13. Hamblin TJ, Davis Z, Gardiner A et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854

    CAS  PubMed  Google Scholar 

  14. Meeker TC, Grimaldi JC, O’Rourke R et al. Lack of detectable somatic hypermutation in the V region of the Ig H chain gene of a human chronic B lymphocytic leukemia. J Immunol. 1988;141:3994–3998

    CAS  PubMed  Google Scholar 

  15. Hamblin T. Chronic lymphocytic leukaemia: one disease or two? Ann Hematol. 2002;81:299–303

    Article  CAS  PubMed  Google Scholar 

  16. Rosenwald A, Alizadeh AA, Widhopf G et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639–1647

    Article  CAS  PubMed  Google Scholar 

  17. D’Arena G, Musto P, Cascavilla N et al. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chornic lymphocytic leukemia. Leuk Lymphoma. 2001;42:109–114

    Google Scholar 

  18. Ibrahim S, Keating M, Do KA et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98:181–186

    Article  CAS  PubMed  Google Scholar 

  19. Jelinek DF, Tschumper RC, Geyer SM et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001;115:854–861

    Article  CAS  PubMed  Google Scholar 

  20. Krober A, Seiler T, Benner A et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410–1416

    CAS  PubMed  Google Scholar 

  21. Hamblin TJ, Orchard JA, Ibbotson RE et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023–1029

    Article  CAS  PubMed  Google Scholar 

  22. Lin K, Sherrington PD, Dennis M et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood. 2002;100:1404–1409

    Article  CAS  PubMed  Google Scholar 

  23. Mainou-Fowler T, Dignum H, Taylor PR et al. Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. Br J Haematol. 2002;118:755–761

    Article  PubMed  Google Scholar 

  24. Hsi ED, Kopecky KJ, Appelbaum FR et al. Prognostic Significance of CD38 and CD20 Expression as Assessed by Quantitative Flow Cytometry in Chronic Lymphocytic Leukemia (CLL). Br J Haematol. 2003;120:1017–1025

    Article  PubMed  Google Scholar 

  25. Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764–1775

    Article  CAS  PubMed  Google Scholar 

  26. Wiestner A, Rosenwald A, Barry TS et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003

    Google Scholar 

  27. Ott G, Kalla J, Hanke A et al. The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features. Leuk Lymphoma. 1998;32:55–63

    CAS  PubMed  Google Scholar 

  28. Argatoff LH, Connors JM, Klasa RJ et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89:2067–2078

    CAS  PubMed  Google Scholar 

  29. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol. 1989;42:567–584

    Article  CAS  PubMed  Google Scholar 

  30. Schlette E, Bueso-Ramos C, Giles F et al. Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol. 2001;115:571–581

    Article  CAS  PubMed  Google Scholar 

  31. Dalton DAG, Goldman JM, Wiltshaw E et al. Prolymphocytic leukemia. Br J Haematol. 1974;27:7–23

    Article  Google Scholar 

  32. Jaffe ES, Harris NL, Stein H et al. Tumours of Haematopoeitic and Lymphoid Tissues. 2001; Lyon: IARC Press

    Google Scholar 

  33. Matutes E, Owusu-Ankomah K, Morilla R et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640–1645

    CAS  PubMed  Google Scholar 

  34. Wong KF, So CC, Chan JK. Nucleolated variant of mantle cell lymphoma with leukemic manifestations mimicking prolymphocytic leukemia. Am J Clin Pathol. 2002;117:246–251

    Article  PubMed  Google Scholar 

  35. Dunphy CH, Perkins SL. Mantle cell leukemia, prolymphocytoid type: a rarely described form. Leuk Lymphoma. 2001;41:683–687

    Article  CAS  PubMed  Google Scholar 

  36. Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood. 2003;101:2464–2472

    Article  CAS  PubMed  Google Scholar 

  37. Mateo M, Mollejo M, Villuendas R et al. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol. 1999;154:1583–1589

    CAS  PubMed  Google Scholar 

  38. Gruszka-Westwood AM, Matutes E, Coignet LJ et al. The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Br J Haematol. 1999;104:600–604

    Article  CAS  PubMed  Google Scholar 

  39. Oscier DG, Matutes E, Gardiner A et al. Cytogenetic studies in splenic lymphoma with villous lymphocytes. Br J Haematol. 1993;85:487–491

    CAS  PubMed  Google Scholar 

  40. Hernandez JM, Garcia JL, Gutierrez NC et al. Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Am J Pathol. 2001;158:1843–1850

    CAS  PubMed  Google Scholar 

  41. Sole F, Salido M, Espinet B et al. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica. 2001;86:71–77

    CAS  PubMed  Google Scholar 

  42. Hernandez JM, Mecucci C, Criel A et al. Cytogenetic analysis of B cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic (FAB) criteria. Leukemia. 1995;9:2140–2146

    CAS  PubMed  Google Scholar 

  43. Gruszka-Westwood AM, Hamoudi R, Osborne L et al. Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes. Genes Chromosomes Cancer. 2003;36:57–69

    Article  CAS  PubMed  Google Scholar 

  44. Corcoran MM, Mould SJ, Orchard JA et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 1999;18:6271–6277

    Article  CAS  PubMed  Google Scholar 

  45. Algara P, Mateo MS, Sanchez-Beato M et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood. 2002;99:1299–1304

    Article  CAS  PubMed  Google Scholar 

  46. Bahler DW, Pindzola JA, Swerdlow SH. Splenic marginal zone lymphomas appear to originate from different B cell types. Am J Pathol. 2002;161:81–88

    PubMed  Google Scholar 

  47. Dunn-Walters DK, Boursier L, Spencer J et al. Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation. Hum Pathol. 1998;29:585–593

    Article  CAS  PubMed  Google Scholar 

  48. Bahler DW, Miklos JA, Swerdlow SH. Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood. 1997;89:3335–3344

    CAS  PubMed  Google Scholar 

  49. Taswell H, Winkelmann R. Sezary syndrome — a malignant reticulemic erythroderma. JAMA. 1961;117:465–472

    Google Scholar 

  50. Vonderheid EC, Bernengo MG, Burg G et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002;46:95–106

    Article  PubMed  Google Scholar 

  51. Flandrin G, Brouet JC. The Sezary cell: cytologic, cytochemical, and immunologic studies. Mayo Clin Proc. 1974;49:575–583

    CAS  PubMed  Google Scholar 

  52. Hoppe RT, Wood GS, Abel EA. Mycosis fungoides and the Sezary syndrome: pathology, staging, and treatment. Curr Probl Cancer. 1990;14:293–371

    CAS  PubMed  Google Scholar 

  53. Kim YH, Bishop K, Varghese A et al. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol. 1995;131:1003–1008

    Article  CAS  PubMed  Google Scholar 

  54. Scarisbrick JJ, Whittaker S, Evans AV et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood. 2001;97:624–630

    Article  CAS  PubMed  Google Scholar 

  55. Bunn PA, Jr., Huberman MS, Whang-Peng J et al. Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination. Ann Intern Med. 1980;93:223–230

    PubMed  Google Scholar 

  56. Lamberg SI, Bunn PA, Jr. Cutaneous T-Cell Lymphomas: Summary of the mycosis fungoides cooperative group-national cancer institute workshop. Arch Dermatol. 1979;115:1103–1105

    Article  CAS  PubMed  Google Scholar 

  57. Vonderheid EC, Sobel EL, Nowell PC et al. Diagnostic and prognostic significance of Sezary cells in peripheral blood smears from patients with cutaneous T cell lymphoma. Blood. 1985;66:358–366

    CAS  PubMed  Google Scholar 

  58. Kim YH, Bishop K, Varghese A et al. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol. 1995;131:1003–1008

    Article  CAS  PubMed  Google Scholar 

  59. Schechter GP, Sausville EA, Fischmann AB et al. Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma. Blood. 1987;69:841–849

    CAS  PubMed  Google Scholar 

  60. Fraser-Andrews EA, Russell-Jones R, Woolford AJ et al. Diagnostic and prognostic importance of T-cell receptor gene analysis in patients with Sezary syndrome. Cancer. 2001;92:1745–1752

    Article  CAS  PubMed  Google Scholar 

  61. Duncan SC, Winkelmann RK. Circulating Sezary cells in hospitalized dermatology patients. Br J Dermatol. 1978;99:171–178

    Article  CAS  PubMed  Google Scholar 

  62. Winkelmann RK, Diaz-Perez JL, Buechner SA. The treatment of Sezary syndrome. J Am Acad Dermatol. 1984;10:1000–1004

    Article  CAS  PubMed  Google Scholar 

  63. Winkelmann RK, Peters MS. Absolute number of circulatory sezary cells. Arch Dermatol. 1981;117:382

    Article  CAS  PubMed  Google Scholar 

  64. Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354–371

    CAS  PubMed  Google Scholar 

  65. Bogen SA, Pelley D, Charif M et al. Immunophenotypic identification of Sezary cells in peripheral blood. Am J Clin Pathol. 1996;106:739–748

    CAS  PubMed  Google Scholar 

  66. Harmon CB, Witzig TE, Katzmann JA et al. Detection of circulating T cells with CD4+CD7-immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol. 1996;35:404–410

    Article  CAS  PubMed  Google Scholar 

  67. Vonderheid EC, Bigler RD, Kotecha A et al. Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sezary syndrome). J Invest Dermatol. 2001;117:654–662

    Article  CAS  PubMed  Google Scholar 

  68. Bernengo MG, Novelli M, Quaglino P et al. The relevance of the CD4+ CD26-subset in the identification of circulating Sezary cells. Br J Dermatol. 2001;144:125–135

    Article  CAS  PubMed  Google Scholar 

  69. Jones D, Dang NH, Duvic M et al. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001;115:885–892

    Article  CAS  PubMed  Google Scholar 

  70. Beck RC, Stahl S, O’Keefe CL et al. Detection of mature T cell leukemias by flow cytometry using anti-T cell receptor Vβ antibodies. Am J Clin Pathol. 2003; In Press

    Google Scholar 

  71. Ingen-Housz-Oro S, Bussel A, Flageul B et al. A prospective study on the evolution of the T-cell repertoire in patients with Sezary syndrome treated by extracorporeal photopheresis. Blood. 2002;100:2168–2174

    CAS  PubMed  Google Scholar 

  72. Schwab C, Willers J, Niederer E et al. The use of anti-T-cell receptor-Vbeta antibodies for the estimation of treatment success and phenotypic characterization of clonal T-cell populations in cutaneous T-cell lymphomas. Br J Haematol. 2002;118:1019–1026

    Article  CAS  PubMed  Google Scholar 

  73. Washington LT, Huh YO, Powers LC et al. A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol. 2002;2:5

    Article  PubMed  Google Scholar 

  74. Beylot-Barry M, Sibaud V, Thiebaut R et al. Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas. J Invest Dermatol. 2001;117:920–926

    Article  CAS  PubMed  Google Scholar 

  75. Weinberg JM, Jaworsky C, Benoit BM et al. The clonal nature of circulating Sezary cells. Blood. 1995;86:4257–4262

    CAS  PubMed  Google Scholar 

  76. Muche JM, Lukowsky A, Heim J et al. Demonstration of frequent occurrence of clonal T cells in the peripheral blood but not in the skin of patients with small plaque parapsoriasis. Blood. 1999;94:1409–1417

    CAS  PubMed  Google Scholar 

  77. Eriksen KW, Kaltoft K, Mikkelsen G et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia. 2001;15:787–793

    Article  CAS  PubMed  Google Scholar 

  78. Leon F, Cespon C, Franco A et al. SHP-1 expression in peripheral T cells from patients with Sezary syndrome and in the T cell line HUT-78: implications in JAK3-mediated signaling. Leukemia. 2002;16:1470–1477

    Article  CAS  PubMed  Google Scholar 

  79. Brender C, Nielsen M, Kaltoft K et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood. 2001;97:1056–1062

    Article  CAS  PubMed  Google Scholar 

  80. Bartlett NL, Longo DL. T-small lymphocyte disorders. Semin Hematol. 1999;36:164–170

    CAS  PubMed  Google Scholar 

  81. Matutes E, Brito-Babapulle V, Swansbury J et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78:3269–3274

    CAS  PubMed  Google Scholar 

  82. Soulier J, Pierron G, Vecchione D et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2001;31:248–254

    Article  CAS  PubMed  Google Scholar 

  83. Matutes E, Catovsky D. Similarities between T-cell chronic lymphocytic leukemia and the small-cell variant of T-prolymphocytic leukemia. Blood. 1996;87:3520–3521

    CAS  PubMed  Google Scholar 

  84. Berliner N. T gamma lymphocytosis and T cell chronic leukemias. Hematol Oncol Clin North Am. 1990;4:473–487

    CAS  PubMed  Google Scholar 

  85. Garand R, Goasguen J, Brizard A et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Francais ďHematologie Cellulaire. Br J Haematol. 1998;103:488–494

    Article  CAS  PubMed  Google Scholar 

  86. Hoyer JD, Ross CW, Li CY et al. True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood. 1995;86:1163–1169

    CAS  PubMed  Google Scholar 

  87. Soma L, Cornfield DB, Prager D et al. Unusually indolent T-cell prolymphocytic leukemia associated with a complex karyotype: is this T-cell chronic lymphocytic leukemia? Am J Hematol, 2002;71:224–226

    Article  PubMed  Google Scholar 

  88. Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol. 2002;19 Suppl:S27–S32

    Article  PubMed  Google Scholar 

  89. Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721–1726

    Article  CAS  PubMed  Google Scholar 

  90. Tuset E, Matutes E, Brito-Babapulle V et al. Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia. Leuk Lymphoma. 2001;42:1379–1383

    Article  CAS  PubMed  Google Scholar 

  91. McKenna RW, Parkin J, Kersey JH et al. Chronic lymphoproliferative disorder with unusual clinical, morphologic, ultrastructural and membrane surface marker characteristics. Am J Med. 1977;62:588–596

    Article  CAS  PubMed  Google Scholar 

  92. Loughran TP, Jr., Kadin ME, Starkebaum G et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med. 1985;102:169–175

    PubMed  Google Scholar 

  93. Loughran TP, Jr. Clonal diseases of large granular lymphocytes. Blood. 1993;82:1–14

    PubMed  Google Scholar 

  94. Karadimitris A, Li K, Notaro R et al. Association of clonal T-cell large granular lymphocyte disease and paroxysmal nocturnal haemoglobinuria (PNH): further evidence for a pathogenetic link between T cells, aplastic anaemia and PNH. Br J Haematol. 2001;115:1010–1014

    Article  CAS  PubMed  Google Scholar 

  95. Lamy T, Loughran TP, Jr. Current concepts: large granular lymphocyte leukemia. Blood Rev. 1999;13:230–240

    Article  CAS  PubMed  Google Scholar 

  96. Chan WC, Catovsky D, Foucar K et al. T-cell large granular lymphocyte leukemia. In: Jaffe ES, Harris NL, Stein H et al., eds. Tumours of Haematopoietic and Lymphoid Tissues. 2001;Lyon: IARC Press

    Google Scholar 

  97. Semenzato G, Zambello R, Starkebaum G et al. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood. 1997;89:256–260

    CAS  PubMed  Google Scholar 

  98. Langerak AW, van Den BR, Wolvers-Tettero IL et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood. 2001;98:165–173

    Article  CAS  PubMed  Google Scholar 

  99. Evans HL, Burks E, Viswanatha D et al. Utility of immunohistochemistry in bone marrow evaluation of T-lineage large granular lymphocyte leukemia. Hum Pathol. 2000;31:1266–1273

    Article  CAS  PubMed  Google Scholar 

  100. Morice WG, Kurtin PJ, Tefferi A et al. Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood. 2002;99:268–274

    Article  CAS  PubMed  Google Scholar 

  101. Lima M, Almeida J, Santos AH et al. Immunophenotypic analysis of the TCR-Vbeta repertoire in 98 persistent expansions of CD3(+)/TCR-alphabeta(+) large granular lymphocytes: utility in assessing clonality and insights into the pathogenesis of the disease. Am J Pathol. 2001;159:1861–1868

    CAS  PubMed  Google Scholar 

  102. Ingen-Housz-Oro S, Bussel A, Flageul B et al. A prospective study on the evolution of the T-cell repertoire in patients with Sezary syndrome treated by extracorporeal photopheresis. Blood. 2002;100:2168–2174

    CAS  PubMed  Google Scholar 

  103. Rabbani GR, Phyliky RL, Tefferi A. A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol. 1999;106:960–966

    Article  CAS  PubMed  Google Scholar 

  104. Morice WG, Leibson PJ, Tefferi A. Natural killer cells and the syndrome of chronic natural killer cell lymphocytosis. Leuk Lymphoma. 2001;41:277–284

    Article  CAS  PubMed  Google Scholar 

  105. Imamura N, Kusunoki Y, Kawa-Ha K et al. Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells. Br J Haematol. 1990;75:49–59

    Article  CAS  PubMed  Google Scholar 

  106. Zambello R, Trentin L, Ciccone E et al. Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood. 1993;81:2381–2385

    CAS  PubMed  Google Scholar 

  107. Morice WG, Hanson CA, Tefferi A et al. Demonstration of aberrant T and NK cell antigen expression in all cases of granular lymphocytic leukemia. Mod Pathol. 2002;15:256a

    Google Scholar 

  108. Lamy T, Liu JH, Landowski TH et al. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood. 1998;92:4771–4777

    CAS  PubMed  Google Scholar 

  109. Epling-Burnette PK, Liu JH, Catlett-Falcone R et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107:351–362

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH (EDH)

    Eric D. Hsi & John L. Frater

  2. Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL (JLF)

    Eric D. Hsi & John L. Frater

Authors
  1. Eric D. Hsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John L. Frater
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Michigan Medical School, Ann Arbor, Michigan

    William G. Finn

  2. Northwestern University Feinberg School of Medicine, Chicago, Illinois

    LoAnn C. Peterson

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Kluwer Academic Publishers

About this chapter

Cite this chapter

Hsi, E.D., Frater, J.L. (2004). Advances in the Diagnosis and Classification of Chronic Lymphoproliferative Disorders. In: Finn, W.G., Peterson, L.C. (eds) Hematopathology in Oncology. Cancer Treatment and Research, vol 121. Springer, Boston, MA. https://doi.org/10.1007/1-4020-7920-6_6

Download citation

  • DOI: https://doi.org/10.1007/1-4020-7920-6_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-7919-1

  • Online ISBN: 978-1-4020-7920-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation